Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NX Prenatal
Prospect, Kentucky, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Developing non-invasive blood-based diagnostic assays using the NeXosome® platform for early detection of adverse pregnancy conditions including pre-term birth (as early as 10 weeks), preeclampsia, and placenta accreta. Planning U.S. launch of NeXosome Preterm Birth Risk Assay; recent studies show high accuracy (e.g., 83% for placenta accreta).
- Therapeutic areas
- Women's Health
- Modalities
- Diagnostic Assay
- Industry
- Molecular Diagnostics
02
Partnerships
Thermo Fisher ScientificHealth Equity Innovation HubHumana Inc.Humana FoundationUniversity of Louisville
Beyond the preview
Go deeper on NX Prenatal.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NX Prenatal.